cellvie AG secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform
cellvie, a pioneer in leveraging the therapeutic potential of mitochondria, together with CSEM, was selected as recipient of an Innosuisse grant with a total project value of more than CHF 700,000.
The project funded focuses on advancing cellvie's mitochondrial isolation process to enable the scalable, safe, and cost-effective manufacturing of its therapy.
“I am excited to partner with CSEM, an expert in the field of automation, on this Innosuisse grant,” commented Dr. Alexander Schueller, founder and CEO of cellvie. “The grant is a recognition of our team's unwavering commitment to and progress in developing mitochondria as a new treatment modality to help patients in dear need.”
The technology's first application will be in ischemia-reperfusion injury, a condition arising in patients receiving an organ transplant, or those suffering from a heart attack. cellvie's first pipeline program is the use of mitochondria for the targeted delivery of oligonucleotides. Both approaches require a GMP-capable and scalable process of manufacturing allogeneic, off-the-shelf mitochondria, the development of which will be accelerated through this Innosuisse grant.
Dr. Alexander Schueller, CEO
tel.: +41-44 591 89 21
About cellvie Inc. and cellvie AG (cellvie)
Founded in the US and operationally headquartered in Zurich in Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of Therapeutic Mitochondria Transplantation at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. Further information can be found at www.cellvie.bio .
About CSEM–Advancing life sciences with impactful solutions
CSEM is a non-profit-oriented public-private Swiss technology innovation center renowned for developing advanced technologies with profound societal impact. Acting as gateway between research and economy, the center's more than 550 employees from 46 countries collaborate with leading universities, scientific institutions, research institutes, and industrial partners. CSEM's mission is to transfer innovations to industries, strengthening the economy. The center is at the forefront of life sciences, combining engineering skills, biological understanding, and cutting infrastructure to revolutionize the field. By bridging precision manufacturing and digitalization, CSEM develops disruptive biosystems that bring the lab to the patient and vice versa. From its advanced biosafety level 2 labs, it leverages cutting-edge technologies like cell microsystems, biomonitoring, lab automation, and AI to create impactful solutions. The center's work narrows the gap between applied sciences and industrialization, enabling standardization and advancements for personalized medicine, diagnostics, and advancements in regenerative medicine. CSEM's tools for life sciences innovation are unlocking new possibilities in healthcare.Back to news